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Abstract
Objective: To study the occurrence of adverse events after administration of a capsular polysaccharide vaccine against 23 pneumococcal 
serotypes in individuals for whom such vaccination is indicated. Methods: This was a prospective study, conducted in a general hospital in 
the city of Sumaré, Brazil, in which 152 individuals were evaluated after intramuscular vaccination with 0.5 mL of the Pneumo 23® vaccine. 
The study variable was subject complaint of at least one symptom forming a temporal nexus with the vaccine (appearing within 48 h after 
its administration). The subjects were evaluated at five to seven days after vaccination. The covariables age, gender and clinical profile were 
tested using the chi-square test and multiple logistic regression, with the level of significance set at 5%. Results: The age of the popula-
tion ranged from 5 to 86 years (mean, 61.8 years). For nearly all (99%) of the subjects, the vaccination evaluated was their first dose of 
the vaccine. Events occurring at the injection site were reported in 36 subjects (23.7%). Of those 36 events, 24 (68%) were mild and had 
no repercussions for the daily activities of the subjects. Pain at the site of the injection was the most common symptom, being reported 
by 97.2% of the subjects. Erythema and localized edema were found in 6.3% and 5.1% of the subjects, respectively. Of the subjects evalu-
ated, 12.8% reported general symptoms (malaise, fever, sleepiness and generalized pain). In the bivariate analysis, none of the covariables 
were found to present a statistically significant correlation with adverse events (p > 0.20). The same held true in the multivariate analysis. 
 Conclusion: Although, the 23-valent pneumococcal vaccine provokes few reactions in the first dose, it is still rarely recommended in the 
region, even for patients at risk.
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Introduction
Vaccination for the prevention of Streptococcus 
pneumoniae infections in at-risk individuals has been 
adopted as a public health measure in various coun-
tries.(1,2) Clinical and epidemiological studies suggest 
that the 23-valent pneumococcal capsular polysac-
charide vaccine is effective in preventing invasive 
disease caused by pneumococci, thereby decreasing 
the numbers of hospitalizations and deaths from 
pneumonia in several regions.(3-5) The antigens 
available in the vaccine induce the formation of 
specific antibodies, increasing the opsonization and 
the phagocytosis of S. pneumoniae. Some authors 
emphasize the limited effectiveness of the vaccine 
in immunocompromised patients with different 
responses according to age, genetic factors, nutri-
tional factors, and clinical situation, as well as the 
short duration of its protection effect.(6-8) Despite 
the controversies on the immunobiological effec-
tiveness in some clinical situations, it has been 
recommended for use in specific groups of indi-
viduals in various countries.(1,9-12)
The pneumococcal polysaccharide vaccine is 
still not widely used in at-risk patients in Brazil, 
although it is available in public hospitals and is 
formally indicated for patients with chronic diseases, 
such as diabetes, chronic bronchitis, emphysema, 
cardiopathy, asplenia, acquired immunodeficiency 
syndrome, renal insufficiency, and liver cirrhosis.(1,11)
Although concerns exist regarding the occur-
rence of adverse events in second doses given at 
intervals of less than five years, most studies consider 
the vaccine safe and minimally reactogenic.(1,10,14) In 
Brazil, there have been few studies of the occurrence 
of adverse events. The present study aims to analyze 
the occurrence of these events after administration 
of the vaccine in individuals for whom such vacci-
nation is indicated in the microregion of the city of 
Sumaré, Brazil. 
Methods
In November of 2004, a prospective investiga-
tion was conducted, involving 152 individuals who 
participated in the vaccination campaign against pneu-
mococcal diseases (receiving the 23-valent vaccine), 
diphtheria and tetanus (adult-type combined diph-
theria-tetanus vaccine) at the Sumaré State Hospital, 
a clinical referral center in the microregion of the 
city of Sumaré (630,000 inhabitants). The campaign 
lasted two days and had been previously disclosed in 
public hospitals and medical services throughout the 
region. General practitioners and specialists working 
at public hospitals received technical information and 
literature on the 23-valent vaccine on the occasion 
of the campaign. The vaccine against diphtheria and 
tetanus was also offered in order take advantage of 
the opportunity to administer this vaccine in those 
who took part in the campaign.
Individuals who took part in the campaign were 
revaluated in relation to whether such immunob-
iological protection was clinically indicated, and 
all gave written informed consent. The informed 
consent form was retained for further contact. By 
the fifth to seventh days after vaccination, individ-
uals were contacted by telephone (or home visits if 
necessary) in order to investigate the occurrence of 
systemic and local (left arm) adverse events, possibly 
related to the 23-valent vaccine. 
Complaints of adverse effects at the site of 
administration were investigated in the 152 individ-
uals receiving the 23-valent vaccine, and systemic 
symptoms were investigated in the 78 individuals 
who received only this vaccine. Since both vaccines 
– against pneumococcal diseases and against 
diphtheria/tetanus – were offered, the systemic 
symptoms of the 74 individuals who received both 
vaccines were not considered. The research was 
approved by the Ethics in Research Committee of 
the State University at Campinas School of Medical 
Sciences (process no. 215/2005). 
The 23-valent vaccine administered was 
Pneumo23® vaccine (lot X0056-1; Aventis Pasteur, 
Madrid, Spain), which was injected intramuscularly 
into the left arm in a dose of 0.5 mL. The vaccine 
against diphtheria and tetanus was administered 
in the right arm. The outcome measure was the 
complaint of at least one symptom related to the 
vaccination. Only local symptoms in the left arm 
with temporal connection with vaccination, that is, 
within 48 h after the administration of the vaccine, 
were considered.(1) The covariables investigated were 
as follows: age, gender, place of residence, clinical 
indication for the vaccine, and reporting having 
chronic diseases.
The local symptoms were classified as being 
of low, mild, or high intensity, based on patient 
reporting. The level of discomfort in performing 
daily activities, the use of medication, and the search 
for medical attention were taken into account, 
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although these perceptions can vary according to 
social and cultural conditions. 
Statistical associations between the occurrence 
of symptoms and the covariables were identified 
using the chi-square test, considering a significance 
level of 5%. After the bivariate analysis, the multiple 
logistic regression model was adjusted considering 
as dependent variable the occurrence of at least one 
symptom, and c-variables were progressively tested 
(stepwise) in the model.(15) The Epi Info program, 
version 6.04, was used to build the database, and 
the Proc Logistic procedure of the Statistics Analysis 
System software was used for the multiple analysis.
Results
A total of 152 individuals were investigated, 
representing 76% of the 200 individuals who took 
part in the campaign. Of the 200 individuals, 47 were 
not found in three attempts, and one declined to 
complete the questionnaire. All 200 individuals 
were vaccinated against pneumococcal diseases, and 
78 received only this vaccine (the 23-valent vaccine). 
In 36 (23.7%) of the 152 individuals evaluated, at 
least one local symptom was observed, possibly 
related to the vaccination against pneumococcal 
diseases. The local symptoms reported were pain, 
erythema, and edema. The profile of the individuals 
studied is shown in Table 1. Systemic symptoms 
were reported by 10 individuals (12.8%).
We observed that most of the vaccinated indi-
viduals (82; 53.9%) were women, and that most 
(57; 37.5%) were in the 60 to 69 years age bracket. 
The age of the studied population ranged from 5 to 
86 years (mean, 61.8 years). Most of the individuals 
(61%) were referred by clinical practitioners from 
basic public health services or specialty outpatient 
clinics in the region. 
Among the comorbidities, the most prevalent 
in the studied population was systemic arterial 
hypertension, which affected 82 patients (53.9%), 
followed by cardiopathy, which was observed in 
46 cases (30.3%). Chronic obstructive pulmonary 
disease and other chronic pulmonary diseases were 
reported by, respectively, 16 (10.5%) and 25 (16.4%) 
of the individuals vaccinated, and only one patient 
presented renal insufficiency. Other diseases, such 
as cirrhosis and liver fibrosis, were reported by 
two individuals (1.4%). In addition, some diseases 
that do not formally constitute an indication for 
vaccination against pneumococcal diseases (vascu-
Table 1 - Profile of vaccinated patients investigated 
during the Sumaré State Hospital campaign, 2004.
n (%)
Gender
Female 82 53.9
Male 69 45.4
Age (years)
< 20 4 2.6
20-29 4 2.6
30-39 3 2.0
40-49 19 12.5
50-59 20 13.2
60-69 57 37.5
70-79 39 25.7
≥ 80 6 3.9
Comorbidities
Arterial hypertension 82 53.9
Cardiopathy 46 30.3
Diabetes Mellitus 37 24.3
Pneumopathy* 25 16.4
COPD 16 10.5
Renal insufficiency 1 0.7
Other 24 15.8
More than one disease was reported per individual; COPD: Chronic 
obstructive pulmonary disease; *excluding COPD.
Table 2 - Local symptoms reported after vaccination with 
the 23-valent vaccine, Sumaré State Hospital, 2004.
Symptoms Intensity n %
Left-arm pain
 
Mild 25 71.4
Moderate 8 22.9
Severe 2 3.7
Subtotal 35 100 (97.2)*
Left-arm Erythema
 
Mild 7 70
Moderate 1 10
Severe 2 20
Subtotal 10 100 (6.6)*
Left-arm Edema
 
Mild 4 50
Moderate 3 37.5
Severe 1 12.3
Subtotal 8 100 (5.5)*
More than one symptom was reported by some individuals; 
*percentage obtained considering the total of individuals with 
local symptoms (n = 36).
lopathy, mental disorders, prostate diseases, and 
others) were reported, accounting for 14.4% of the 
sample (Table 1).
Table 2 indicates the type and intensity of 
the principal symptoms at the site of application 
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reported by the 36 patients. Low intensity local 
symptoms presented the highest incidence. Only 
five patients reported high intensity local symp-
toms, 2 reporting pain, 2 reporting erythema, and 
1 reporting edema. Local pain was the most preva-
lent symptom, reported by 35 individuals, being of 
low intensity in 25 cases (15.8% of the vaccinated 
individuals). Although present, left-arm erythema 
and edema were less common, being reported by 
10 (6.6%) and 8 (5.3%) patients, respectively.
Of the 36 individuals who reported some local 
complaint after vaccination, 11 (30.6%) reported 
having used medications at home. Only one indi-
vidual sought medical attention (due to fever and 
malaise after vaccination). 
In cases of local adverse event complaints, the 
duration of the reported symptoms was investigated. 
Table 3 shows that most patients reported symp-
toms of short duration, for an average of 1.5 days 
after vaccination, not exceeding two days in 83.3% 
of the cases. Only one individual (2.8%) complained 
of persistent and prolonged pain (for more than six 
days) at the site of application.
Of the 78 patients who were vaccinated only 
against pneumococcal diseases, 10 (12.8%) reported 
systemic symptoms after vaccination (Table 4). In 
59% of the cases, the symptoms were reported by 
individuals older than 65 years of age. In 3 cases 
(3.8%), local and systemic systems were reported: 
in a 73-year-old man, local pain and edema were 
intense and were accompanied by malaise and 
chills; in a 40-year-old man, local pain was mild 
but was accompanied by headache and nausea; in 
a third case, pain and erythema were mild but were 
accompanied by fever, although no medication was 
used. 
The bivariate analysis identified no associations 
between the occurrence of any local or systemic 
adverse event and any of the covariables studied 
(p > 0.20; Table 5), which was confirmed in the 
multiple logistic analysis. 
Discussion
Although the campaign attendance was limited, 
we studied patients submitted to clinical follow-up 
evaluation at the basic health services and specialty 
clinics in the microregion who had never before been 
vaccinated against pneumococcal diseases. This fact 
suggests a low coverage of vaccination, considering 
that during annual vaccination campaigns against 
influenza, when vaccination against pneumococcal 
diseases is also offered, the doses did not reach 10% 
of the population that had sought medical atten-
tion as of 2005. There are no available data on the 
coverage of pneumococcal vaccination in Brazil. 
Although the coverage of the vaccine against influ-
enza virus is adequate and increasing, the use of the 
pneumococcal vaccine in Brazil, as in other coun-
tries, is still quite limited.(7) In a study evaluating 
the reasons for the lack of demand for vaccination 
against pneumococcal diseases, one of the most 
Table 3 - Duration of local symptoms after pneumococcal 
23-valent vaccination (n = 36), Sumaré State Hospital, 
2004.
Duration of pain (days after vaccine) n %
< 1 day 7 19.4
1 13 36.1
2 10 27.8
3 5 13.9
6 1 2.8
Total 36 100.0
Table 4 - Systemic symptoms reported by individuals who 
received pneumococcal 23-valent vaccine only (n = 78), 
Sumaré State Hospital, 2004.
Symptoms* n %
At least one symptom 10 12.8
Malaise 5 6.4
Fever 2 2.6
Body pain 1 1.3
Chills 1 1.3
Headache 3 3.8
Nausea 1 1.3
Prostration and/or sleepiness 2 1.3
*More than one symptom was reported by some individuals.
Table 5 - Bivariate analysis of the occurrence of local 
symptoms after pneumococcal 23-valent vaccine and 
covariables, Sumaré State Hospital, 2004.
Variable χ2 p df
Gender 0.07 0.78 2
Age 2.85 0.72 5
Comorbidity 0.66 0.42 2
Diphtheria and Tetanus vaccine 0.02 0.89 2
City of residence 6.77 0.75 10
General symptoms 0 0.97 2
χ2: chi-square test; df: degrees of freedom.
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common was that people are afraid of the potential 
adverse events, as well as the lack of formal recom-
mendations by physicians.(16)
The finding that local adverse events occurred 
in 23.7% of the individuals evaluated in the present 
study was similar to that found by some authors(17) 
and lower than those found by other authors, who 
reported rates of 30 to 50%.(10,14,18) These numbers 
can be influenced by the demographic, social, and 
cultural features of the studied population, as well 
as by the composition of the specific vaccine lot. 
One relevant fact is that severe adverse reactions 
were not observed among the studied patients, 
thereby confirming evidence in the literature of the 
fact that they are rare.(1,18,19)
Most local adverse reactions were reported as 
mild, not interfering with the daily activities of the 
patients. Most local and systemic events appear 
within the first 24 h after the vaccine administra-
tion and did not last more than 48 h. This pattern 
has been described in other studies.(1,13) 
Our finding that systemic complaints after vacci-
nation were reported by 12.8% of the individuals 
is similar to the 11.3% found in another study(17) 
involving revaccinated individuals and considerably 
higher than the approximately 2% reported in yet 
another study.(14) It is important to emphasize that 
the systemic symptoms observed in these patients 
were, for the most part, nonspecific (malaise, 
sleepiness, and prostration), mild, and reported by 
individuals of more than 65 years of age with chronic 
disease. It is possible that the individuals investi-
gated attributed an excessive number of systemic 
symptoms to the 23-valent vaccine. However, fever, 
which is a more specific symptom, was reported 
by 2.6% of the individuals, which is similar to the 
percentage found by other authors.(17) Nausea has 
been reported as a possible postvaccination event in 
other studies.(17)
Almost all patients vaccinated in the campaign 
evaluated were receiving their first dose of the 
vaccine. Some authors reported a higher frequency 
of local adverse reactions in revaccinated individ-
uals, specifically in those vaccinated at intervals of 
less than five years. Nevertheless, there is consensus 
that the occurrence of symptoms possibly related to 
vaccination or revaccination is not a contra-indi-
cation to immunobiological protection due to its 
benefits.(1,6,13,18)
Especially in immunocompromised individuals, 
some authors, in a systematic review of randomized 
clinical trials, have identified low effectiveness of 
the vaccine in ‘high risk’ patients, that is, patients 
with renal immunodeficiency, blood cancer, neph-
rotic syndrome, systemic lupus erythematosus, and 
alcoholism. However, among elderly individuals, as 
well as individuals with diabetes, chronic pulmonary 
disease, or cardiopathy, the immunological response 
has been evaluated as appropriate or compensatory 
due to the impact on the prevention of morbidity 
and mortality from invasive disease caused by 
S. pneumoniae.(13,14,21-23)
Among the patients analyzed, it was not possible 
to compare vaccinated and revaccinated individuals, 
since only one individual was revaccinated in the 
campaign, and that individual had been received 
the first dose more than five years prior. This result 
indirectly suggests the low coverage of the vaccina-
tion against pneumococcal diseases among patients 
with chronic diseases under clinical follow-up treat-
ment in the region of Sumaré and for whom such 
vaccination is formally indicated. 
In the present study, the 23-valent pneumo-
coccal capsular polysaccharide vaccine was found 
to be minimally reactogenic in the first dose and 
was rarely recommended by physicians in the 
region under study. The disclosure of experiences 
confirming the minimal reactogenicity and safety of 
the 23-valent vaccine might stimulate basic health 
services and specialty clinics to vaccinate individuals 
for whom such vaccination is clinically indicated. 
Given the importance of formal recommendation 
of immunobiological protection by the physician, 
wider dissemination of such information among 
health professionals could improve the vaccination 
coverage. The implementation of strategies to iden-
tify such patients in hospitals and emergency rooms 
could favor an increase in the specific protection of 
at-risk groups.(24) 
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